Biotech and pharma marketing runs through physicians, payers, and patients on cycles that stretch across quarters, with half the channels blocked from third-party tracking. We build the attribution and measurement layer that shows what's working without pretending marketing alone wrote the prescription.
The Problem
Third-party tracking doesn't work on the channels that matter most
HCP portals, medical congress apps, and closed physician networks block the pixel-based tracking that consumer marketing analytics relies on. Rep-triggered emails, speaker program attendance, and medical information requests generate real engagement signal, but it lives in separate systems that don't talk to your web analytics – leaving most teams with a detailed picture of website traffic and almost nothing on the channels physicians actually use.
The buying cycle has three decision-makers and none of them convert on your site
A prescription depends on a physician's clinical judgment, a payer's formulary decision, and a patient's willingness to start and stay on therapy – three tracks that move on different timelines, sometimes 12-18 months apart. Standard marketing attribution models assume one buyer moving through one funnel; applying that model to a formulary win eight months after a KOL engagement produces numbers that look precise and mean nothing.
Leadership wants a marketing-to-Rx line that doesn't actually exist
Commercial leadership asks marketing to prove ROI the way a demand-gen team would – dollars in, pipeline out. But prescription trends move on clinical data, competitive launches, payer coverage changes, and rep detailing, with marketing as one input among several. Teams that promise direct causation to keep budget end up either fabricating a model nobody trusts or quietly stop measuring at all.
Data lives in silos that were never built to be joined
Your CRM has rep call data. Your MAP has email and portal engagement. Claims vendors have prescription trends on a lag, and congress vendors run their own systems entirely. Without a deliberate integration layer, each team reports its own numbers in its own review, and nobody can answer a basic question: which HCPs are engaged and moving toward prescribing behavior.
How We Help
Our initial assessment maps every engagement signal you actually have access to – rep CRM activity, HCP portal logins, email and content engagement from the MAP, speaker program and congress attendance, medical information requests, and whatever claims data your commercial team already licenses. Most companies are surprised how much signal exists once it's inventoried in one place instead of scattered across five vendor dashboards.
Strategy development builds a multichannel measurement model suited to a non-linear buying cycle, not a borrowed SaaS funnel. We define engagement tiers for HCPs based on the combination of signals that correlate with prescribing readiness, and set explicit boundaries on what the model can and can't claim, so commercial leadership gets a tool for prioritizing outreach, not a causal guarantee marketing can't back up.
Execution builds the dashboards and reporting cadence your brand teams and commercial leadership actually use, connecting CRM, MAP, and claims data into a unified HCP engagement view tagged by therapeutic area and brand. Field teams get a prioritized list of engaged-but-unconverted HCPs; brand leads get channel performance by engagement tier instead of raw impression counts that say nothing about physician intent.
Measurement here means correlation with discipline, not attribution theater. We report engagement trends alongside prescription and formulary outcomes, explicit about what marketing likely contributed to versus what competitive and clinical factors drove. It's slower to build than a dashboard with a fake conversion number on it, but it's the version that survives a medical affairs review and still gets used a year later.
What we deliver
- HCP engagement scoring model – combines portal, email, rep, and program signal into tiers tied to prescribing readiness, not a single-touch score
- Multichannel measurement framework built for non-linear, multi-stakeholder cycles instead of a borrowed direct-response funnel
- Unified reporting layer connecting CRM, MAP, and claims/prescription data by therapeutic area and brand
- Formulary and prescription-trend correlation reporting with explicit boundaries on what marketing can and can't claim to have caused
The teams that keep their analytics budget aren't the ones who claim marketing caused the prescription – they're the ones who can show which HCPs were engaged before the formulary win and stop pretending they know exactly why it happened.
Our Methodology
Our 90-day marketing analytics build starts with a data inventory, not a dashboard template. Phase one catalogs every system holding engagement or outcome data – CRM, MAP, congress and speaker vendors, claims feeds – and identifies what can realistically be joined given your governance constraints, while interviewing brand and commercial leadership on the decisions the analytics need to inform.
Phase two designs the engagement model and reporting structure, running in parallel with your MLR process rather than after it, so the disclaimers and boundaries that keep the model honest are built in from the start, not bolted on when legal objects.
Phase three implements the dashboards and trains the teams who use them. Unlike a generic analytics agency retrofitting a SaaS attribution model onto pharma data, we build the system around the reality that a prescription has multiple stakeholders on a long, non-linear path – and say so in the reporting instead of hiding it behind a confident-looking dashboard.
How We Work
Initial engagements run 3-4 months. The first 30 days are the data audit – cataloging source systems, assessing what's joinable under your compliance constraints, and confirming which decisions the finished system needs to support.
Days 31-60 build the engagement model and reporting architecture with your commercial ops and IT teams on data access, and with MLR reviewers on how correlation claims get worded – usually the slowest phase, since governance sign-off moves slower than a typical SaaS integration.
Days 61-90 implement dashboards, train field and brand teams, and set the review cadence. Weekly sessions track build progress; monthly reviews with commercial leadership walk through the engagement-to-outcome correlation reporting, with the boundaries of the model stated plainly every time.
- HCP engagement visibility across previously siloed channels
- Prioritized field and digital outreach based on engagement tier rather than list size
- Defensible, MLR-reviewed correlation reporting between marketing activity and formulary/prescription trends
If your biotech & pharma company needs marketing analytics leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a marketing analytics engagement cost for a biotech or pharma company?
Engagements typically run $60K-$140K depending on how many data sources need to be integrated and how many brands or therapeutic areas are in scope. A single-brand build with two or three source systems sits at the lower end; a multi-brand portfolio pulling from CRM, MAP, congress vendors, and claims data sits higher. That's meaningfully less than a dedicated commercial analytics headcount.
Can marketing analytics actually prove marketing caused a prescription or formulary win?
No, and we won't tell you it can. A prescribing decision involves clinical data, payer coverage, competitive dynamics, and rep detailing alongside marketing – no honest model isolates marketing as the sole cause. What we build shows correlation between engagement and outcomes with the confounding factors named, which is what holds up in an MLR audit.
How do you measure HCP engagement without third-party tracking on physician portals?
We pull first-party data your organization already owns – MAP email and content engagement, portal login activity where you control the platform, rep CRM call notes, speaker program and congress attendance, and medical information request logs. None of these require third-party pixels. The work is in joining systems that were never built to talk to each other, not in finding new tracking methods that don't exist in this space.
How long before we see useful output from a marketing analytics build?
The data audit and initial engagement visibility typically land by day 30-45, which already gives field and brand teams a better view of who's engaged than they had before. Correlation reporting against prescription and formulary trends needs at least one full reporting cycle – often a quarter or two – to show a meaningful pattern, since pharma buying cycles are long by nature.
What makes Winston Francois different from a generic marketing analytics agency?
Most analytics agencies bring a SaaS attribution model built for a single-buyer, short-cycle funnel and try to force pharma data into it. We build the measurement model around the actual buying process – physician, payer, and patient on different timelines – and we build the MLR review into the process instead of treating it as a blocker to work around.
What size or stage of biotech or pharma company is the right fit for this service?
Commercial-stage companies with at least one product on the market and an active field or digital HCP engagement motion get the most value, since there's engagement data to work with. Pre-commercial companies preparing for launch can also benefit from setting up the measurement infrastructure early rather than retrofitting it after launch. The first step is a data audit to see what's actually available to measure.
